Catherine Rivet - Ph.D. Defense

Primary tabs

Co-Advisor: Dr. Melissa Kemp (Biomedical Engineering, GT/Emory)Co-Advisor: Dr. Hang Lu (Chemical and Biomolecular Engineering, GT) Committee: Dr. Robert Butera (Electrical & Computer Engineering/Biomedical Engineering, GT/Emory) Dr. Cheng Zhu (Biomedical Engineering, GT/Emory) Dr. Niren Murthy (Bioengineering, UC-Berkeley) Dr. Harry Asada (Mechanical Engineering, MIT)The goal of cancer immunotherapies is to boost the immune system’s ability to detect tumor antigens and mount an effective anti-tumor immune response. Currently, adoptive T cell transfer therapy (ACT), the administration of ex vivo expanded autologous tumor-specific T cells, is one of the most promising immunotherapies under development; however, its efficacy has been limited so far with a mere 10% complete remission rate in the most successful clinical trials. The prolonged ex vivo culture process is a potential reason for this ineffectiveness because the transfused cells may reach replicative senescence and immunosenescence prior to patient transfer. The objective of this thesis is to offer two approaches towards an improvement of treatment efficacy. First, we generated a ‘senescence metric’ from the identification of biomarkers that can be used in the clinic towards predicting age and responsiveness of ex vivo expanded T cells. The second approach is to understand at the molecular level the changes that occur during ex vivo expansion to devise improved ACT protocols. In particular, we focused on the shift towards a pro-oxidizing environment and its potential effects on calcium signaling. The combined development and application of microfluidic technologies and computational models in this thesis facilitated our investigations of the phenotypic and signaling changes occurring in T cells during the progression towards immunosenescence. Our findings of altered T cell properties over long term culture provide insight for the design of future cancer immunotherapy protocols.


  • Workflow Status: Published
  • Created By: Chris Ruffin
  • Created: 06/14/2012
  • Modified By: Fletcher Moore
  • Modified: 10/07/2016

Target Audience